In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litig., No. 13-cv-2445 (E.D. Pa.)

In the Suboxone case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a class of direct purchasers of Reckitt Benckiser’s opioid addiction drug, Suboxone.  The class alleges that Reckitt took several actions to suppress competition from generic versions of Suboxone, including reformulating Suboxone into a film (for which generic versions of Suboxone tablets could not be substituted by pharmacists), sabotaging efforts to create a joint REMS program, and filing a baseless citizens petition.  Faruqi & Faruqi was appointed co-lead counsel by the Court.

Suboxone Complaint

Suboxone EDPa Class Certification Opinion

Suboxone Third Circuit Class Certification Order

Suboxone Third Circuit Class Certification Opinion

Suboxone Motion for Preliminary Approval of Settlement

Suboxone Order Granting Preliminary Approval of Settlement

Notice of Settlement

Claim Form

Class Counsel Motion for Attorneys’ Fees

Class Counsel’s Motion For Attorneys’ Fees, Reimbursement Of Expenses And Service Awards For The Named Plaintiffs

Notice Of Joinder By Class Representative Rochester Drug Co-Operative, Inc. and Absent Class Member Miami-Luken, Inc.

Opinion and Order of Final Approval of Settlement, Attorney Fees and Incentive Awards